Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 14, 2020

Baricitinib-remdesivir trial achieves reduced recovery time for Covid-19 patients

The National Institute of Allergy and Infectious Diseases (NIAID) in the US has announced results from a Phase III study which show how baricitinib plus remdesivir reduced recovery time for people hospitalised with Covid-19.

The National Institute of Allergy and Infectious Diseases (NIAID) in the US has announced results from a Phase III study which show how baricitinib plus remdesivir reduced recovery time for people hospitalised with Covid-19.

Discovered by Incyte and licensed to Eli Lilly and Company, baricitinib is an anti-inflammatory drug while remdesivir is an antiviral treatment developed by Gilead Sciences.

The peer-reviewed results from the second iteration of the National Institutes of Health (NIH) Adaptive COVID-19 Treatment Trial (ACTT-2) were published in The New England Journal of Medicine.

The data supported the US Food and Drug Administration’s (FDA) decision to grant emergency use authorisation (EUA) for the combination in hospitalised patients with Covid-19 needing supplemental oxygen.

In May, the trial sponsored by the NIAID was launched to assess remdesivir plus baricitinib for treating Covid-19.

The Phase III study enrolled 1,033 patients from 67 trial sites in eight countries.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

In the trial, participants were randomly given either oral baricitinib tablets in combination with intravenous (IV) remdesivir or oral placebo tablets plus IV remdesivir.

Data from the study showed that the combination reduced the median recovery time in hospitalised Covid-19 patients from eight days to seven days.

On receiving the combination therapy, those needing high-flow oxygen or non-invasive ventilation during hospitalisation had the largest benefit. Data showed that their median time to recover was reduced from 18 days to ten days.

At day 15, conditions of subjects significantly progressed on receiving baricitinib plus remdesivir.

Eli Lilly immunology global brand development lead and New England Journal of Medicine paper author Anabela Cardoso said: “Presently, there are limited published placebo-controlled data assessing treatment options to manage the symptoms and progression of Covid-19.

“We need high-quality research such as the ACTT-2 study to evaluate therapies to fight this pandemic and are pleased that this medicine is now available for patients under EUA.”

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU